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FGF21 is a critical metabolic regulator, pivotal for
fasting adaptation and directly regulated by PPARa
in rodents. However, the physiological role of
FGF21 in man is not yet defined and was investigated
in our study. Serum FGF21 varied 250-fold among 76
healthy individuals and did not relate to age, gender,
body mass index (BMI), serum lipids, or plasma glu-
cose. FGF21 levels had no diurnal variation and were
unrelated to bile acid or cholesterol synthesis. Keto-
sis induced by a 2 day fast or feeding a ketogenic diet
(KD) did not influence FGF21 levels, whereas a 74%
increase occurred after 7 days of fasting. Hypertrigly-
ceridemic nondiabetic patients had 2-fold elevated
FGF21 levels, which were further increased by 28%
during fenofibrate treatment. FGF21 circulates in hu-
man plasma and increases by extreme fasting and
PPARa activation. The wide interindividual variation
and the induction of ketogenesis independent of
FGF21 levels indicate that the physiological role of
FGF21 in humans may differ from that in mice.
INTRODUCTION
The fibroblast growth factor (FGF) family comprises at least 22
members involved in development, differentiation, cell survival
and growth, wound healing, and tumor formation (Itoh and Or-
nitz, 2004; Ornitz and Itoh, 2001).
Recently, FGF19, FGF21, and FGF23 have been described as
structurally and functionally diverted (Nishimura et al., 1999, 2000;
Shimada et al., 2001; Xie et al., 1999). These FGFs exert hor-
mone-like metabolic effects by interacting with FGF receptors (Fu-
kumoto, 2008) dependent on the presence of the beta-glucuroni-
dases Klotho or beta-Klotho as coreceptors (Goetz et al., 2007;
Kharitonenkov et al., 2007a; Kurosu et al., 2007; Lin et al., 2007;
Ogawa et al., 2007; Urakawa et al., 2006; Wu et al., 2007). FGF23Cis linked to phosphate balance (Fukumoto and Yamashita, 2007;
Masuyama etal., 2006),while FGF19 is a strong metabolic regulator
in mice (Fu et al., 2004; Tomlinson et al., 2002). Like its mouse ho-
mologFGF15,FGF19 isalsoanegative regulatorofbileacidsynthe-
sis in mice (Inagaki et al., 2005) and humans (Lundasen et al., 2006).
FGF21, abundant in the liver (Nishimura et al., 2000), is structur-
ally related to FGF19, and FGF21-transgenic animals are resistant
to diet-induced weight gain and fat accumulation (Kharitonenkov
et al., 2005). Diabetic rodents given FGF21 display improved blood
glucose, insulin, and triglycerides (TG), (Kharitonenkov et al., 2005)
asdodiabeticmonkeys (KharitonenkovandShanafelt, 2008;Khar-
itonenkov et al., 2007b). FGF21 has also been shown to be a direct
target gene of PPARa in mouse liver (Badman et al., 2007; Inagaki
et al., 2007; Lundasen et al., 2007). Hepatic FGF21 mRNA is in-
duced in mice that are fasted or exposed to a ketogenic diet
(KD), partly in a PPARa-dependent manner (Badman et al., 2007;
Lundasen et al., 2007), and changes in FGF21 hepatic expression
correlate with its plasma levels (Badman et al., 2007). Thus, FGF21
has been described as a novel metabolic regulator (Kharitonenkov
et al., 2005) and as a master hormonal switch for liver ketogenesis
and overall metabolic adaptation to fasting (Reitman, 2007).
Since little information is available on FGF21 functions in man,
we carried out studies to analyze circulating levels of FGF21 in var-
ious conditions, such as in normal and hypertriglyceridemic (HTG)
humans and during metabolic perturbations induced by fasting,
a KD, and by fenofibrate treatment. Our results show that FGF21
circulates in humans at highly variable levels. While no increases
in serum FGF21 levels were observed following a 48 hr fast or
KD treatment despite an induction of ketosis, fasting for one
week significantly increased serum FGF21. FGF21 levels were
also elevated in HTG patients, while treatment with the PPARa ag-
onist fenofibrate lowered serum TG and increased serum FGF21.
RESULTS
FGF21 Is Present in Human Serum and Its Levels
Are Highly Variable between Individuals
We first evaluated the distribution of serum FGF21 and its rela-
tion to different metabolic parameters. When FGF21 wasell Metabolism 8, 169–174, August 6, 2008 ª2008 Elsevier Inc. 169
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Circulating FGF21 in Humansassayed by ELISA in samples from 76 healthy normal-weight vol-
unteers with an age span of 20–80 years, its levels showed con-
siderable interindividual variation ranging from 21 to 5300 pg/mL.
The skewed distribution (Figure 1A) became normal upon log
transformation (not shown). There was no difference between
genders (see insert in Figure 1A). In all 76 individuals, the mean
and median FGF21 levels were 450 pg/mL and 156 pg/mL,
respectively. FGF21 levels did not correlate to body mass index
(BMI), age, blood glucose, serum total, LDL or HDL cholesterol,
or TG (not shown). Neither did we find a correlation between se-
rum FGF21 and whole body cholesterol synthesis (assessed by
serum lathosterol) or bile acid synthesis (evaluated by serum
7a-hydroxy-4-cholesten-3-one, [C4]).
Individual Serum FGF21 Levels Are Stable with Time
We next evaluated if circulating FGF21 has a diurnal rhythm, as
has FGF19 (Lundasen et al., 2006). Samples from 5 healthy vol-
unteers drawn every 90 min over a 25.5 hr period (Galman et al.,
2005) were assayed for FGF21. There were no major changes re-
lated to feeding and fasting. In one individual, subject D, FGF21
levels were stable throughout the observation period (Figure 1B).
In three subjects, FGF21 levels increased somewhat from mid-
night to 1:30 AM. However, comparison of the means of the rel-
ative levels of all subjects did not show any significant changes
during the period as compared to the start value (9 AM), indicat-
ing that FGF21 levels are stable in healthy subjects.
FGF21 Is Only Induced by Prolonged Fasting
Since fasting increases hepatic FGF21 mRNA expression and
plasma FGF21 in mice (Badman et al., 2007; Inagaki et al.,
2007; Lundasen et al., 2007), we first tested if this also occurs
in humans by analyzing samples from a series of experiments.
First, four subjects who had been fasted overnight continued
to refrain from food the next day (Galman et al., 2005). Blood
was collected every hour from 9 AM to 4 PM. This short fasting
did not increase serum FGF21 levels (Figure 1C). Instead,
FGF21 levels were reduced the first hours of sampling. For the
group, this transient reduction was significant at 11 AM and at
noon (Figure 1D). FGF21 increased for the following hours so
that by 4 PM the levels had returned to initial levels.
To evaluate if longer fasting could alter circulating FGF21, we
analyzed serum from 7 healthy subjects prior to and after 48 hr of
fasting (Arner et al., 2003). During this period, subjects lost 2.5 kg
(3.4%) in BW (Figure 2A). As expected, there was a strong 40-
fold increase in serum 3-hydroxybutyrate, and plasma glucose
was reduced (Figures 2B and 2C). There were, however, no
changes in FGF21 levels (Figure 2D). Thus, in man, a ketogenic
response induced by a 2 day fast occurred without alterations
in circulating FGF21.
To further explore if a more energy-deprived state would alter
FGF21 levels in humans, we assayed samples from a third study
(Hafstrom et al., 1988), where 5 females with rheumatoid arthritis
were sampled before and at the end of a 7 day water fast. Body
weight was reduced by 4.2 kg (6.9%), whereas serum 3-hy-
droxybutyrate levels increased 70-fold (Figures 3A and 3B). In
thisexperiment, serumFGF21 increased by74%, from913ng/mL
to 1592 ng/mL (p < 0.05) (Figure 3C). Thus, after a 7 day fast,
plasma FGF21 increased in all individuals although the levels
reached were still within the normal range.170 Cell Metabolism 8, 169–174, August 6, 2008 ª2008 Elsevier Inc.We next evaluated whether the ingestion of a KD may increase
plasma levels of FGF21. For this purpose, we assayed FGF21 in
samples from a set of children sampled before and on a KD. As
expected, 3-hydroxybutyrate increased, and plasma glucose
was reduced (Figures 3D and 3E). However, plasma FGF21, al-
though showing a similar level and broad variation as in adults
(Figure 1), was not increased on the KD (Figure 3F).
Fenofibrate Treatment Increases Serum FGF21
PPARa regulates FGF21 transcription necessary for the fasting
response in mice, and PPARa ligands increase FGF21 transcrip-
tion in human hepatocytes (Badman et al., 2007; Inagaki et al.,
2007; Lundasen et al., 2007). Fibrates, a class of TG-lowering
drugs, are PPARa ligands (Forman et al., 1997), and FGF21 treat-
ment of diabetic animals reduces plasma TG (Kharitonenkov
et al., 2005, 2007b). We therefore questioned if fibrate treatment
in humans can increase serum FGF21. For this purpose, 19 nor-
mal-weight, nondiabetic patients with primary HTG were treated
for 3 weeks with placebo or fenofibrate (200 mg/day) using a dou-
ble-blind crossover design. On placebo, plasma TGs were 5-fold
higher than in the 76 controls described above. Interestingly,
baseline serum FGF21 was doubled as compared to normals
(Figure 4A). Among HTG patients, however, there was no corre-
lation between FGF21 and TG levels. Fenofibrate treatment re-
duced plasma TG 60%, whereas serum FGF21 levels increased
significantly by 28%, from 964 pg/mL to 1233 pg/mL (Figure 4B).
DISCUSSION
The metabolic regulator FGF21 controls glucose/lipid homeo-
stasis in rodents and nonhuman primates and is critical in mice
in the physiological response to fasting, presumably acting in
part as a circulating hormone (Badman et al., 2007; Inagaki
et al., 2007). Since it is unclear whether these functions are pres-
ent in man, we searched for evidence for a metabolic role of
FGF21 in humans by measuring FGF21 levels in serum at differ-
ent metabolic and pharmacological conditions.
Fasting morning levels of FGF21 in sera from 76 healthy, non-
obese subjects revealed a broad 250-fold interindividual varia-
tion from 21 pg/mL to 5300 pg/mL. The mean level of 450 pg/mL
is similar to that reported in mice (Badman et al., 2007). In normal
subjects, we found no relations between FGF21 and serum cho-
lesterol, TG, blood glucose, BMI, age, gender. We also found no
relations between FGF21 and cholesterol or bile acid synthesis,
the latter two evaluated from serum markers. There were no clear
diurnal changes in serum FGF21 indicating that feeding or fast-
ing overnight does not alter FGF21 levels.
The fact that subjects with a high or a low FGF21 concentra-
tion maintained their individual levels when sampled for 25 hr in-
dicates that there is an intrinsic variation in FGF21 metabolism in
healthy subjects. Since we could not identify any modifying fac-
tors related to FGF21 levels, it is tempting to speculate that var-
iation in serum concentration is not important for metabolic reg-
ulation in healthy humans. Indeed, the manifestation of FGF21
requires either disease condition or a metabolic challenge in
healthy rodents or monkeys (Kharitonenkov and Shanafelt,
2008; Kharitonenkov et al., 2005, 2007b). Furthermore, in anal-
ogy with insulin and leptin biology, high levels of FGF21 may
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Circulating FGF21 in HumansFigure 1. FGF21 Is Highly Variable between Individuals but Stable with Time
(A) Frequency distribution of serum FGF21 in healthy subjects from samples obtained after overnight fast from 76 healthy volunteers (39 women and 37 men) with
an age span from 20–80 yr. The insert shows distribution in males and females; bars show SD.
(B) Absence of diurnal changes in serum FGF21. Blood samples were drawn from five healthy volunteers every 90 min over a 25.5 hr period (Galman et al., 2005).
The first sample was taken at 9 AM after an overnight fast. All subjects received the same standardized meals at the indicated times (arrows) and slept in darkness
from 12:30 AM to 7 AM. There were no significant differences when all time points (expressed as percentage of initial value) were compared to the first sampling
(Dunnett’s test).
(C) Serum FGF21 during acute fasting (prolonged overnight fasting 9 AM–4 PM) in four subjects. Four of the subjects shown in (B) (subjects A–D) were studied 2–6
weeks after the first session. Blood was collected every hour from 9 AM to 4 PM after overnight fast. During the experiment, no food was ingested, only water was
consumed ad libitum. FGF21 values are expressed as percentage of the initial value taken at 9 AM.
(D) Mean values and SEM (bars) from the four subjects in panel C. The ‘‘*’’ shows p < 0.05 when compared to the first sampling (Dunnett’s test).suggest either a state of hormonal resistance or an adaptive
individual response to combat metabolic disturbances.
The lack of a clear diurnal rhythm in serum FGF21 is in contrast
to FGF19, which has two peaks during daytime (Lundasen et al.,
2006). Also, our data suggest that serum FGF21 is not likely influ-
enced by bile acid metabolism since there were no correlations
to markers of bile acid or cholesterol synthesis.
FGF21 has been implied as an important circulating metabolic
regulator in fasted mice (Badman et al., 2007; Inagaki et al.,
2007). There, PPARa activation-induced FGF21 hepatic expres-
sion/secretion has been hypothesized to promote ketogenesis in
situations of energy deprivation by stimulating lipolysis in adi-
pose tissue and promoting fatty acid oxidation in the liver;
thus, inducing the energy conserving state of torpor by signaling
to the brain (Reitman, 2007). In normal humans, food deprivation
during the day did not increase FGF21 levels; if anything, there
was a transient reduction in FGF21 instead. Extending the fast-
ing period in normal humans to 2 days resulted in a 40-fold in-Ccrease of 3-hydroxybutyrate. Despite this, there was no change
in serum FGF21 levels (Figure 2D). Thus, in contrast to the situa-
tion in mice (Inagaki et al., 2007; Reitman, 2007), serum FGF21
levels are not crucial for the general fasting response in humans.
However, since we did not assay FGF21 directly in liver or adi-
pose tissues (Zhang et al., 2008), it cannot be excluded that a lo-
cal expression of FGF21 is induced at all stages of fasting. This
possibility warrants future investigation.
Fasting for 7 days was achieved as part of a study on how food
deprivation may influence disease activity in patients with rheu-
matoid arthritis (Hafstrom et al., 1988). Conclusions from this ex-
periment should be drawn with some caution. However, medica-
tion was withdrawn at least two weeks before the study, and initial
FGF21 levels were not different from those in healthy subjects. Af-
ter this long period of fasting, the levels of 3-hydroxybutyrate
were doubled (6 mmol/L) as compared to those reached after
a 2 day fast (3 mmol/L). Although the levels of FGF21 increased
in all patients, they were however still within the normal range.ell Metabolism 8, 169–174, August 6, 2008 ª2008 Elsevier Inc. 171
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conserving state of torpor, and it may be that the function of
FGF21 as ‘‘master switch of fasting’’ is particular in species de-
pendent on torpor for survival (Reitman, 2007). The metabolic
rate is about 10-fold higher in mice than in humans, and energy
stores are thus rapidly depleted in mice upon food deprivation.
Interestingly, fasting of mice for 8 h did not increase plasma
FGF21 (Badman et al., 2007). This time period may correspond
to the present 2 day fast where we saw no FGF21 increases in
man. A 24 hr fast in mice should correspond to about a week of
fasting in humans, a situation where we observed increased se-
rum FGF21 levels. As mentioned, the levels of serum ketones
were about double compared to the 2 day fast, which may indi-
cate that circulating FGF21 could be important to boost the
fasting response during starvation but is not causative to its ini-
tiation in humans. Thus, although our FGF21 data following dif-
ferent periods of fasting in humans are in line with the results
shown in rodents, they suggest that FGF21 may have some-
what different physiological roles in man and mice; and that it
is not likely to be a key regulator of hepatic ketone production
in humans. Ketosis is also induced during a KD, which in mice
is dependent on hepatic FGF21 production and release (Bad-
man et al., 2007). We could however not see any increases of
circulating FGF21 in a set of children clearly ketotic from such
a diet regimen, further supporting a different role of FGF21 in
man.
Figure 2. Effects of 2 Days of Fasting in Seven Healthy Volunteers
(Three Women and Four Men)
(A) Body Weight.
(B) 3-hydroxybutyrate.
(C) Plasma Glucose.
(D) Serum FGF21.172 Cell Metabolism 8, 169–174, August 6, 2008 ª2008 Elsevier IncIn patients with primary HTG, serum FGF21 also varied con-
siderably, but the mean level in those individuals was about twice
that observed in healthy subjects. At this stage, though, it is dif-
ficult to make any firm conclusions about the possible patho-
physiological relevance of that finding. It is important to note,
however, that we did not find any correlation between TG and
FGF21 levels within the HTG group, in accordance with what
we observed in the healthy group. Considering the known effects
of FGF21 treatments in animals, we predicted that FGF21 levels
would be lower in the HTG patients. If similar findings of elevated
FGF21 levels in HTG can be confirmed in other patient series, it
would be more logical to ascribe them to some form of FGF21
resistance with compensatory increases in FGF21 secretion. In
two recent reports on humans with varying degrees of obesity,
positive correlations between FGF21 levels and TG concentra-
tions in serum have been observed (Chen et al., 2007; Zhang
et al., 2008).
Figure 3. Prolonged Fasting, but not a KD, Increases Serum FGF21
(A–C) Effects of 7 days of fasting in five patients with rheumatoid arthritis (Haf-
strom et al., 1988). (A) indicates body weight; (B) indicates 3-hydroxybutyrate;
and (C) indicates serum FGF21.
(D–F) Effects of a KD given to 17 children with pharmacoresistant epilepsy. (D)
indicates plasma glucose; (E) indicates 3-hydroxybutyrate, and (F) indicates
serum FGF21..
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Circulating FGF21 in HumansTreatment of HTG patients with fenofibrate increased serum
FGF21 levels. This indicates that also in man, PPARa activation
increases the synthesis and secretion of FGF21. The impact of
the fibrate-induced elevation in FGF21 on the hypolipidemic re-
sponse cannot be determined from the present work. However,
the degree of stimulation was moderate, and no correlation be-
tween the percentage changes in serum TG and FGF21 was
found. This lack of relation together with our finding that serum
TG and FGF21 levels were not correlated among normal or
HTG subjects when analyzed separately indicates that circulat-
ing serum FGF21 levels may not be causally related to serum
TG. An alternative explanation could be that the individual sensi-
tivity to FGF21 varies, a possibility supported by the wide range
of serum FGF21 levels both in normal and HTG subjects.
In conclusion, endogenous FGF21 is readily detectable in se-
rum from human subjects. There is a large interindividual varia-
tion, and HTG appears to be linked to elevated levels. Prolonged
fasting and fenofibrate treatment both increase FGF21, although
ketogenesis can clearly be induced independent of serum
FGF21 levels, indicating that FGF21 may have different physio-
Figure 4. Serum FGF21 Is Increased in HTG Patients and Following
Fenofibrate Treatment
(A) Serum TG and FGF21 in 19 HTG subjects compared to 76 healthy subjects.
(B) Effects of fenofibrate treatment in HTG patients on serum TG and FGF21.
Bars indicate SD.Clogical roles in man and mice. Further studies monitoring the re-
sponses following the administration of exogenous FGF21 in
normal, hyperlipidemic, and diabetic humans will be of great
interest.
EXPERIMENTAL PROCEDURES
Subjects and Study Design
From a material of 435 healthy volunteers, 76 subjects matched for gender and
age were selected to serve as healthy controls. Information on selection and
other measures of samples are shown online in Table S1 . For studies on diur-
nal changes of FGF21, samples from 5 healthy subjects were used as detailed
elsewhere (Galman et al., 2005). Subjects fasted for 2 days were 7 normal vol-
unteers from a previous study (Arner et al., 2003); some characteristics of
these subjects are given online in Table S2. The subjects fasted for 7 days
were 5 female patients with rheumatoid arthritis described in detail online in
Table S3. The effect of the KD was evaluated in 17 children with pharmacore-
sistant epilepsy; details on these patients are shown online in Table S4. The
effect of fenofibrate was evaluated on 20 HTG subjects, as detailed online in
Table S5.
All subjects or their parents gave informed consent to participation in the
studies, which had been approved by the Ethics Committee of Karolinska
Institutet. When not otherwise indicated, analyzed blood was drawn in the
morning after overnight fast, and serum or plasma was separated and stored
at 80C.
Serum Analyses
FGF21 levels were assayed in duplicate by sandwich ELISA developed in-
house, using affinity chromatography purified polyclonal and monoclonal
antibodies generated against recombinant human FGF21 protein. The intra-
assay coefficient of variation (CV) was <6.3%, and interassay CV was 8.4%.
Microtiter 96 well plates were coated with a monoclonal anti-FGF21 AB (clone
61-6G9) o/n at 4C (5 mg/mL, 0.1 mL/well). All assay steps were carried out in
0.1 mL/well additions with 1 hr incubations at room temperature in duplicate.
After washing and blocking, standards and samples were added. Polyclonal
anti-FGF-21 (1:10000) was added and detected with donkey-anti-rabbit-
HRP (1:5000) from Jackson ImmunoResearch (West Grove, PA). O-phenylene-
diamine dihydrochloride enzyme substrate was added, and the plate was in-
cubated at room temperature for 10 min. Color development was stopped
with H2SO4. Absorbance was read at 450 nm in a plate reader. The standard
curve was constructed using SOFTMax Pro 3.1.2 software, Molecular Devices
(Toronto, Canada). The standard curve range was 0.0195 ng/mL –10 ng/mL.
The sensitivity of the ELISA was 0.039 ng/mL, calculated as the mean absor-
bance value of duplicate measurement of zero standards plus three times the
SD. Human FGF19, FGF23, FGF1, and FGF2 (R&D Systems) were tested for
crossreactivities, and no such reactivitiy was observed. The 7a-hydroxy-4-
cholesten-3-one (C4) concentration in serum or plasma was assayed by
high pressure liquid chromatography (HPLC) (Galman et al., 2003). Unesteri-
fied lathosterol was determined in 50 mL serum by isotope dilution-mass spec-
trometry (Galman et al., 2005). Plasma total, LDL and HDL cholesterol, TG, and
glucose were determined using routine colorimetric techniques.
Statistics
Significances of differences between groups were tested by ANOVA accord-
ing to Dunnett (Figures 1B and 1D) or by unpaired and when applicable, by
paired student t test after logarithmic transformation. GraphPad Prism v4.03
was used (GraphPad Software, San Diego, CA).
SUPPLEMENTAL DATA
Supplemental Data include five tables and Supplemental References and can
be found at http://www.cellmetabolism.org/cgi/content/full/8/2/169/DC1/.
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